Orphan oncology focus Ascelia Pharma concentrates on rare cancer conditions with Orphan Drug Designation potential, presenting a clear pathway for commercialization and partnership opportunities in niche oncology markets.

Orviglance expansion Orviglance is in late-stage development (Phase 3) for liver imaging in patients with kidney impairment, offering a differentiated MR-contrast solution that could drive collaborations with radiology centers, hospitals, and imaging providers seeking safer alternatives to gadolinium-based agents.

Oncoral opportunity Oncoral’s oral irinotecan tablet aims to improve convenience and safety over IV infusion for gastric cancer, suggesting partnerships with oncology clinics, patient support programs, and payers focusing on treatment adherence and reduced hospitalization costs.

Strategic funding & leadership Recent financing and leadership changes, including new CFO appointments and ongoing funding rounds, indicate opportunities to engage investors and strategic partners who value pipeline potential, enabling co-development or royalty-based collaborations.

Clinical data momentum Abstracts and presentations at ESGAR and related radiology congresses signal active data generation on Orviglance, offering channels for sponsored study collaborations, speaking engagements, and vendor partnerships with imaging centers and research networks.